EVMN Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 7.47%, SMA50 28.22%, SMA200 30.82%). The stock’s 14-day RSI is 54.91 (neutral), while the ATR of 3.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.79% below its high and over 91.79% above its low. Average 10-day trading volume of 392.44 thousand shares is below the 3-month average of 640.99 thousand, indicating normal recent market interest.

Our AI price prediction model suggests that Evommune, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.75%, with price expected at $24.12 by April 07, 2026, within a range of $18.84 to $29.46 3-Month Outlook: Projected rise of 10.99%, reaching $23.33 by June 22, 2026, with a range of $22.77 to $23.83. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 24, 2027, within a range of $0.00 to $0.00.

Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $35.00. The high target offers 209.23% upside. The low target suggests 66.51% downside. The mean target is $44.78. This offers 113.04% upside. Evommune, Inc. earnings surprise history is a mixed track record. The quarter that ended December 11, 2025, missed forecasts by 623.77%. The prior quarter beat by -5.02%. Over the last six quarters, Apple has recorded several small beats. These include -5.02% in December 03, 2025.

Evommune, Inc. (NYSE:EVMN) shares are flat 7.48% year-to-date currently trading near 52-week highs band. Valuation shows Evommune, Inc. trading at a premium to the broader market with a P/E of -9.72. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $44.78, suggesting 113.04% upside. Our AI forecast model points to short-term strength (14.75% over two weeks), a medium-term rise (10.99% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Evommune, Inc. (NYSE:EVMN) closed at $21.02 USD, losing -$2.43 (-10.36%) from the previous close of $23.45. The stock is currently mid-range between its 52-week high and low $13.88 and $33.20. With a market capitalization of about $270.55 million, Evommune, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 639.33 thousand shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Evommune, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Luis C. Pena, the company employs approximately 45 people and listed since November 06, 2025. Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Evommune, Inc. trades at a P/E ratio of -9.72, slightly below the S&P 500 average, with a price-to-sales ratio of 21.02 and a price-to-book ratio of 3.26 trading at moderately above to book value. The P/FCF stands at -3.56, also above market averages.